Product Reports Resources Pricing Login Book a demo
LP profile

Memorial Sloan - Kettering Cancer Center

Government Non Profit · Founded 1884 · Greenwich, United States

#94 LP Ranking #1 of 196 LPs

A cancer treatment and research institution in New York City

75 VC firms backed
$7.0B AUM
~$70M Allocated to VC (est. 1%)
01 · Background

Who Memorial Sloan - Kettering Cancer Center is.

Historical Background
Memorial Sloan Kettering Cancer Center (MSK) was founded in 1884 as the New York Cancer Hospital, the first institution in the United States dedicated exclusively to cancer treatment. The modern entity was formed in 1960 through the consolidation of Memorial Hospital and the Sloan-Kettering Institute. In 1971, the National Cancer Act designated MSK as one of the country's first three Comprehensive Cancer Centers.
Source of Capital
As a non-profit organization, MSK's capital is derived from a combination of patient revenue, research grants from entities like the National Institutes of Health, and philanthropic donations from individuals, foundations, and corporations. Historically, the institution has received substantial support from prominent philanthropic families, including the Rockefellers and the Sloans.
Major Events
A significant event was the 1960 consolidation of Memorial Hospital and the Sloan-Kettering Institute, which formally combined the institution's clinical care and research arms.
Allocation Strategy
MSK's investment activities are primarily focused on advancing its non-profit mission of patient care and research, rather than operating as a traditional venture capital or private equity investor. The institution allocates capital toward internal research and development, the creation of spin-off companies to commercialize its discoveries, and strategic collaborations with biotechnology and pharmaceutical companies. MSK's Office of Technology Development facilitates the commercialization of intellectual property, often through licensing agreements and the formation of new ventures, indicating a strategy of investing in its own scientific breakthroughs.
02 · Fund commitments

The funds Memorial Sloan - Kettering Cancer Center backs.

Memorial Sloan - Kettering Cancer Center is a limited partner in 75 funds. 14 of them place in the Power Law Investor Ranking; those lead, best-ranked first.

03 · Allocation

How Memorial Sloan - Kettering Cancer Center’s fund book is spread.

The 75 funds Memorial Sloan - Kettering Cancer Center backs, by where the manager is headquartered and how many funds that manager has raised.

Where those managers are based

By fund headquarters.

  • North America 5979%
  • Europe 1013%
  • Rest of world 68%

United States 58 · United Kingdom 7 · China 2 · Hong Kong 2

How established those managers are

Managers grouped by how many funds they have raised — across the 55 of 75 with a fund history on record.

Emerging funds · 16
Established funds · 39
7 1
5 2
4 3
10 4
10 5-6
7 7-9
8 10-14
4 15+
Funds raised by the manager
04 · Exits

Memorial Sloan - Kettering Cancer Center’s biggest exits.

Portfolio companies that IPO’d or were acquired at $1B+, with the valuation recorded at exit and — for those still public — their value today. Exit events come from each company’s funding-round history; entry stage from Memorial Sloan - Kettering Cancer Center’s transaction record.

Ajax Therapeutics
$2.3B acquisition · 2026
Health
Sellas Life Sciences
IPO · 2008
Now $2.2BHealth
ORIC Pharmaceuticals
IPO · 2020
Now $1.1BHealth
$1.0B acquisition · 2013
Health
05 · Direct investments

The companies Memorial Sloan - Kettering Cancer Center backs directly.

Memorial Sloan - Kettering Cancer Center holds 27 companies directly, separate from the funds it commits to as a limited partner. Broken down by headquarters country, sector, entry stage and current growth stage.

By countryCount
  1. USA24
  2. Australia1
  3. Bermuda1
  4. China1
By sectorCount
  1. Health27
By growth stageCount
  1. Early Growth13
  2. Late Growth9
  3. Breakout Stage5
06 · Portfolio market map

Inside Memorial Sloan - Kettering Cancer Center’s portfolio.

The 26 highest-funded portfolio companies, of 27 tracked.

ORIC Pharmaceuticals
Health · Unicorn
$1.1B
Flare Therapeutics
Health
$340M
Gritstone Oncology
Health
$1.6M
Affini-T Therapeutics
Health
$700M
Ajax Therapeutics
Health · Unicorn
$2.3B
Aragon Pharmaceuticals
Health · Unicorn
$1.0B
Y-mAbs Therapeutics
Health
$332M
Jounce Therapeutics
Health
Cota Healthcare
Health
$160M
Juniper Biosciences
Health
$160M
Blue Note Therapeutics
Health
$131M
Sellas Life Sciences
Health · Unicorn
$2.2B
Moda Biotechnology
Health
$11M
Abintus Bio
Health
$63M
Seneca Therapeutics
Health
$16M
Bridge Medicines
Health
$40M
PHLIP
Health
$18M
Perceptive Navigation
Health
$2.0M
Isabl
Health
$500K
Lime Therapeutics
Health
Summit Biomedical Imaging
Health
SurgiVance
Health
Cytogel Pharma
Health
Epi One
Health
$4.0M
Nine Diagnostics
Health
$320K
Radiopharm Theranostics
Health
$1.1M
07 · Portfolio founders

Where Memorial Sloan - Kettering Cancer Center’s portfolio founders come from.

34 founders across the 27 highest-funded portfolio companies — by current location, university attended, and the companies they worked at before founding. Sourced from the founder records the API links to each portfolio company.

LocationCount
  1. United States29
  2. United Kingdom2
  3. Australia1
  4. China1
  5. Peru1
UniversityCount
  1. Harvard Business School3
  2. University of Cambridge3
  3. Emory University2
  4. University of California, San Diego2
  5. University of Glasgow2
  6. University of Illinois Urbana Champaign2
  7. Case Western Reserve University1
  8. Columbia University1
  9. Florida State University1
  10. George Brown College1
Previous companyCount
  1. Memorial Sloan - Kettering Cancer Center7
  2. Chiron Corporation3
  3. Harvard University3
  4. Dana-Farber Cancer Institute2
  5. Pressure Pipe Inspection Company2
  6. Abbott1
  7. Advanced Accelerator Applications1
  8. Apple Tree Partners1
  9. AstraZeneca1
  10. Bersin by Deloitte1